BMSSC
ESPR

B. Metzler seel. Sohn & Co’s Esperion Therapeutics ESPR Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,019
Closed -$337K – 689
2021
Q1 		$337K Hold
12,019
– – 0.01% 599
2020
Q4 		$338K Buy
+12,019
New +$360K 0.01% 585

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

B. Metzler seel. Sohn & Co's ESPR Position: Q2 2021 in Review

B. Metzler seel. Sohn & Co sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 12,019 shares — an estimated $337K sold.

B. Metzler seel. Sohn & Co first reported a position in ESPR in Q4 2020 and held it in 2 quarters. The position peaked at $338K in Q4 2020. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • B. Metzler seel. Sohn & Co reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 12,019 Esperion Therapeutics shares in Q2 2021, an estimated $337K.
  • B. Metzler seel. Sohn & Co first reported a position in Esperion Therapeutics in Q4 2020 and held it in 2 quarters.
  • B. Metzler seel. Sohn & Co's Esperion Therapeutics position peaked at $338K in Q4 2020.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2021, filed 30 Aug 2021.